The sudden and severe US cuts to grants from the world’s largest health research funder threaten to unravel the medical research landscape in South Africa. A crucial question now is whether the government will turn this crisis into an opportunity for renewal, write Marcus Low and Nathan Geffen.
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
Amid major disruptions caused by aid cuts from the United States government, the health department aims to enrol a record number – an additional 1.1 million – of people living with HIV on life-saving antiretroviral medicine this year. Experts tell Spotlight it can’t be business as usual if this ambitious programme is to have a chance of succeeding. Ufrieda Ho reports.
Following President Donald Trump’s decision to suspend foreign aid, President Cyril Ramaphosa can display great leadership by meeting with leaders of wealthy countries and convincing them to increase spending to support the health systems of poorer countries, write Nathan Geffen and Marcus Low.
Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
Whether or not someone living with HIV in South Africa gets a one- or three-months’ supply of antiretrovirals at a time depends partly on the clinic where they happen to go for HIV care. Ahead of World AIDS Day 2024, Elri Voigt unpacks the legal and policy issues relating to prescriptions and HIV medicine refills and asks why people living with HIV are treated so differently in different parts of the country.
HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.
Once South Africa had closed the door on state-sponsored AIDS denialism in 2008, a critical question was how to offer HIV treatment to as many eligible people as possible as quickly as possible. Given that the health system did not have enough doctors for the job, it was decided in 2010 to rope in nurses to help out. Tiyese Jeranji asks where things stand with Nurse Initiated and Managed Antiretroviral treatment (NIMART) 13 years later.
National Treasury has proposed a R1 billion cut to HIV funding. This has come about because – rather than seeing the reduced price of antiretroviral treatment as an opportunity to scale up treatment coverage and strengthen other interventions to address the HIV epidemic – the Department of Health has seen it as an opportunity for cost-containment. However, the HIV epidemic is not over and savings owing to cost reductions should not simply be returned to Treasury, argue Matshidiso Lencoasa and Mila Harding.
It is estimated that over 65% of the global HIV burden is in sub-Saharan Africa. Now, in an attempt to propel African voices and perspectives in the next phase of the HIV response in Africa, a group of Africans established an African-led HIV control working group (HCWG). They are all experts from the continent who have come together to develop consensus perspectives on the long-term sustained control of HIV and prioritise the systems and capabilities to achieve it. Drs Yogan Pillay and Izukanji Sikazwe explain the thinking behind the new working group and set out their objectives.
Specially trained and accredited pharmacists in South Africa will now be allowed to dispense medicines to prevent HIV and TB and to treat uncomplicated HIV without a doctor’s script. This is because the North Gauteng High Court this week ruled against an application by a private doctors’ association attempting to block the initiative. Catherine Tomlinson unpacks the judgment and rounds up some responses.
In what is likely one of the largest treatment rollouts in South African history, well over four million people living with HIV have started taking the antiretroviral dolutegravir since its introduction around four years ago. Now, according to a recent study published in the Lancet medical journal, use of dolutegravir in South Africa is associated with more people staying on treatment and higher rates of viral suppression. Elri Voigt unpacks the study findings and assesses progress in the country’s switch to dolutegravir-based HIV treatment.
